- ARCH Venture Partners has announced it closed two new funds called ARCH Venture Fund X and ARCH Venture Fund X Overage at $1.46 billion
ARCH Venture Partners has announced it closed two new funds called ARCH Venture Fund X and ARCH Venture Fund X Overage. These two funds have a combined $1.46 billion to invest in early-stage biotechnology companies. And ARCH is deploying Fund X and Fund X Overage to invest in early-stage companies.
ARCH is going to frequently co-invest in a company with both funds, but Fund X Overage will be utilized in fewer deals requiring larger investments. The limited partners include endowments, family offices, sovereign wealth funds, and other institutional investors.
Fund X and Fund X Overage follow ARCH Venture Fund IX and ARCH Venture Fund IX Overage — which closed in 2016 with a combined $1.1 billion. And this is a big jump from ARCH Venture Fund VIII and ARCH Venture Fund VIII Overage (closed in 2014 with a combined $560 million).
Some of ARCH’s early-stage portfolio investments included Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Receptos, Agios Pharmaceuticals, Vir Biotechnology, Sage Therapeutics, bluebird bio, Codiak Biosciences, Denali Therapeutics, GRAIL, Karuna Therapeutics, Beam Therapeutics, Lyell Immunopharma, Sana Biotechnology, Brii Biosciences, Twist Bioscience, Aviron, Ikaria, Gossamer Bio, Fate Therapeutics, Array Biopharma, Adolor, Quanterix, 908 Devices, Unity Biotechnology, Hua Medicine, deCODE Genetics, and Homology Medicines. Vir Biotechnology, Alnylam Pharmaceuticals, VBI Vaccines, Brii Biosciences, and Sana Biotechnology are currently working to develop COVID-19 therapeutics;
Quanterix is working on advancing technology that can help with clinical testing needs and support clinical trial continuity. Twist Bioscience is advancing genomic and gene engineering tools used in COVID-19 therapeutic and vaccine development. And Bellerophon’s inhaled nitric oxide (iNO) delivery system recently received emergency expanded access approval from the FDA for treatment of COVID-19.
The Managing Directors involved in these funds are Robert Nelsen, Keith Crandell, Kristina Burow, Mark McDonnell, Steve Gillis, and Paul Thurk.
Key Quotes:
“ARCH has always been driven to invest in great science to impact human health. There isn’t a better illustration of our principles than our all-in battle against COVID-19. The healthcare revolution will be accelerated by the changes that are happening now and we are excited to continue to invest aggressively in risk takers doing truly transformational science.”
ARCH Venture Partners co-founder and Managing Director Robert Nelsen
“Our companies bring cutting-edge science, tools and talent to bear in developing medicines for a wide range of diseases and conditions faced by millions. With these two new funds, we are continuing that work with urgency and a deep sense of purpose. We invest at all levels, whether it’s fifty thousand dollars or hundreds of millions, so that each company and each technology has the best chance to advance and change the landscape.”
ARCH Venture Partners Managing Director Kristina Burow.
“ARCH remains committed to our mission of the last 35 years, advancing the most promising innovations from leading life science and physical sciences research to serve the worldwide community by addressing critical health and well-being challenges. ARCH has been privileged to found, support and invest in groundbreaking new companies pursuing advancements in infectious disease, mental health, immunology, genomic and biological tools, data sciences and ways of reimagining diagnostics and therapies.”
ARCH Venture Partners co-founder and Managing Director Keith Crandell.
“ARCH is still willing to sit down with a scientist with a lab notebook to develop and translate great science into great companies. Fundamental science is what drives us and creating new diagnostics and disease modifying and curative therapies is what motivates us.”
ARCH Venture Partners Managing Director Steve Gillis
